Results showed that the OS of colorectal cancer, AML, and MM patients and the distant recurrence-free survival (DRFS) of soft tissue cancer in the MYL5 high-expression group were significantly longer than the MYL5 low-expression group (Figures 3(q)–3(t)). This evidence concerns the gene MYL5 and Miyoshi myopathy.